Opko Health OPK Pharmaceutical — Intangible Amortization

Other segment segments

Similar metrics at other companies

CPRXAmortization Expenses Of Intangible Asset

$9.7M+3.8%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Amortization of intangibles

$8.1M-1.9%

NBIXIntangible Amortization

$100K-90.0%

ADEAIntellectual Property Licensing — Intangible Amortization

$15.93M+13.1%

PDFSAmortization Of Intangible Assets Including Cost Of Amortization

$2.06M+94.8%

PATKManufacturing — Intangible Amortization

$20.26M-2.2%

Questions, answered.

What is Opko Health's pharmaceutical — intangible amortization?

Opko Health (OPK) reported pharmaceutical — intangible amortization of $16.43M in Q1 2026.

How has Opko Health's pharmaceutical — intangible amortization changed year-over-year?

Opko Health's pharmaceutical — intangible amortization increased by 2.0% year-over-year, from $16.11M to $16.43M.

What is the long-term trend for Opko Health's pharmaceutical — intangible amortization?

Over 2 years (2023 to 2025), Opko Health's pharmaceutical — intangible amortization has grown at a -0.2% compound annual growth rate (CAGR), from $65.84M to $65.59M.

What does pharmaceutical — intangible amortization mean?

The systematic allocation of the cost of intangible assets, such as patents, licenses, and acquired technology, over their estimated useful lives within the pharmaceutical segment. This non-cash expense reflects the consumption of the segment's intellectual property value.